A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NCT05171647)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
2. CD20+ aggressive lymphoma as determined by the local hemopathology laboratory from the following diagnoses by 2016 World Health Organization classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS); high-grade B-cell lymphoma (NOS or double/triple hit); transformed follicular lymphoma; follicular lymphoma Grade 3b
3. Have disease relapsed or refractory to at least one prior systemic therapy for aggressive non-Hodgkin's lymphoma (aNHL)
4. Participants who have received only one prior line of therapy must be ineligible for autologous stem cell transplant (ASCT)
5. Measurable disease
6. Adequate hepatic, hematologic, and renal function
7. Estimated creatinine clearance (CrCl) ≥ 30 mL/min by Cockroft-Gault method or other institutional standard methods
8. Negative HIV test at screening. Participants with a positive HIV test at screening are eligible provided that, prior to enrollment, they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count of at least 200 microliters, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (51 Sites)

• City of Hope Cancer Center — Duarte, California
• St. Luke's Hospital — Chesterfield, Missouri
• Ascension Seton Infusion Center — Austin, Texas
• MD Anderson Cancer Center — Houston, Texas
• Hospital Aleman — Buenos Aires,
• Instituto Alexander Fleming — Buenos Aires,
• FUNDALEU — Buenos Aires,
• Hospital Italiano de Buenos Aires — Ciudad Autonoma Buenos Aires,
• Hospital Erasto Gaertner — Curitiba, Paraná
• Hospital das Clinicas - UFRGS — Porto Alegre, Rio Grande do Sul
• Hospital das Clínicas FMRP-USP — Ribeirão Preto, São Paulo
• Hospital Sao Jose — São Paulo, São Paulo
• D'or Instituto de Pesquisa e Educação — São Paulo,
• Hamilton Health Sciences - Juravinski Cancer Centre — Hamilton, Ontario
• Princess Margaret Hospital — Toronto, Ontario
• Chum Hopital Notre Dame — Montreal, Quebec
• Sichuan Cancer Hospital — Chengdu,
• Fujian Medical University Union Hospital — Fuzhou,
• Cancer Center, Sun Yat-sen University of Medical Sciences — Guangzhou,
• Tianjin Cancer Hospital — Tianjin,
• Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech — Wuhan,
• Henan Cancer Hospital — Zhengzhou,
• Soroka Medical Center — Beersheba,
• Ichilov Sourasky Medical Center — Tel Aviv,
• Kyushu University Hospital — Fukuoka,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.